Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23366306 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL1460181 | 0.77 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL517923 | 0.76 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL865926 | 0.76 | — | — | |
| SCHEMBL130951 | 0.75 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL22092385 | 0.75 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL7771621 | 0.75 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL9138159 | 0.75 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL10779479 | 0.74 | — | — | |
| SCHEMBL21814803 | 0.73 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327447-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | 89BIO, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-118414344-A | Chemical synthesis of cytidine-5' -monophosphate-N-glycyl-sialic acid | 89生物公司 | 2024-07-30 | — | — | CN | disclosed |
| EP-4225766-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | 89Bio, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023122616-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | 89BIO, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| US-7527934-B2 | Labeled substrate conjugates for identifying enzyme inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060057658-A1 | Labeled substrate conjugates for identifying enzyme inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2006025983-A2 | LABELED SUBSTRATE CONJUGATES FOR IDENTIFYING ENZYME INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-5721245-A | ANTIINFLAMMATORY AGENTS, RESPIRATORY SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0384349-B1 | Substituted pyrroles | HOFFMANN LA ROCHE (CH) | 1994-04-27 | — | — | EP | disclosed |
| US-4999345-A | Anticoagulants | BASF AKTIENGESELLSCHAFT (DE) | 1991-03-12 | — | — | US | disclosed |
| EP-0384349-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | ALDH1A1 1219/4885SMN1; SMN2 4478/4885POLB 2383/4885 |
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | ALDH1A1 192/4885SMN1; SMN2 1107/4885POLB 4364/4885 |
| US-20240327447-A1 | CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID | NEU2, NEU1, FUT5 | ALDH1A1 809/4885SMN1; SMN2 2176/4885POLB 1547/4885 |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | ALDH1A1 1219/4885SMN1; SMN2 4478/4885POLB 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.